Friday, 16 October 2026European Markets

SYNERGIE Stock 11.29% Up Today

Loading stream...

(vianews) - the market ended the session with synergie (sdg.pa) jumping 11.29% to €34.50 on wednesday, after two successive sessions in a row of gains. cac 40 rose 0.12% to €7,583.43, following the last session's upward trend on what was a somewhat positive trend exchanging session today.

synergie's last close was €31.00, 10.79% under its 52-week high of €34.75.

about synergie

synergie se provides human resources management and development services for companies and institutions in france, belgium, other northern and eastern europe, italy, spain, portugal, canada, and australia. it offers temporary work, recruitment, out-placement, social engineering, consultancy, and training services. the company serves various specialized sectors and industries, such as renewable energy, transport and logistics, construction and public works, healthcare, agri-food, and tertiary sectors. synergie se was founded in 1969 and is headquartered in paris, france.

earnings per share

as for profitability, synergie has a trailing twelve months eps of €3.51.

pe ratio

synergie has a trailing twelve months price to earnings ratio of 9.83. meaning, the purchaser of the share is investing €9.83 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 14.82%.

volatility

synergie's last week, last month's, and last quarter's current intraday variation average was 0.33%, 0.04%, and 1.17%.

synergie's highest amplitude of average volatility was 1.63% (last week), 0.82% (last month), and 1.17% (last quarter).

volume

today's last reported volume for synergie is 10798 which is 351.79% above its average volume of 2390.

yearly top and bottom value

synergie's stock is valued at €34.50 at 21:31 est, below its 52-week high of €34.75 and way higher than its 52-week low of €28.50.

revenue growth

year-on-year quarterly revenue growth grew by 5.6%, now sitting on 3b for the twelve trailing months.

more news about synergie (sdg.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com